Clinical Trial Update: Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing decitabine plus CHOP versus CHOP in untreated peripheral T-cell lymphoma evaluates efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• CHOP regimen
• Decitabine (Decitabine)

Snippet

Sponsor: Southwest Hospital, China | Conditions: Peripheral T-cell Lymphoma | Phase 3 | Status: UNKNOWN